As per our report, the size of the global HGH market is forecasted to reach USD 7627 million by 2029 from USD 5312 million in 2024, growing at a CAGR of 7.50% from 2024 to 2029.
The growth hormone plays a vital role in regulating body composition and primarily spurs growth in children. However, when there is an issue producing these hormones by pituitary glands, they may not correctly develop bone and muscles. In these cases, human growth hormone injections are prescribed by doctors.
The growing number of health disorders among children, primarily due to changes in food habits is one of the key factors driving the growth of the global HGH market. In addition, the rise in awareness of treatment procedures is propelling the market's growth. Besides, the market is growing with a surge in the research institutes in the biotechnology field, leveraging the demand of the global human growth hormone market. Rising neuropsychiatric cases and increasing government funds for R & D in the endocrinology sector fuel market demand. In addition, advanced technologies are introduced in the healthcare domain to improve the services' quality helping the HGH market grow. With the growing number of approvals by the FDA and other government organizations, public and private organizations have taken some initiatives to promote healthcare-related services and policies among the developed and under-developing companies and accelerate the human growth hormone market. Increasing older people is one-factor fostering market demand.
Rising disposable income in the urban population and people's demand the effective treatment procedures is to set up growth opportunities for the market. The increasing consumption rate of these drugs in significant applications is likely to boost the market's growth. In addition, the growing prevalence of adopting the latest technologies in producing the pills at low cost may positively impact the HGH market demand.
The ongoing usage of the medicines is likely to produce side effects impacting the global HGH market growth negatively. Strict government rules in approving the drugs are restraining the market growth. The pharmaceutical companies facing ups and downs while producing drugs impede the market's growth. The treatment's cost culture is very high and will likely limit the demand for human growth hormone. Fluctuations in the productivity of drugs in pharmaceutical companies are also hindering the growth of the global human growth hormone market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Analysed |
By Application, Distribution Channel, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
The online pharmacy segment is projected to account for a significant share of the HGH market during the forecast period. In existing countries like India and China, the trend of online pharmacies is increasing daily. In addition, the high perforation of pharmacies is also growing in North America and Europe.
The Asia Pacific Human growth hormone market follows North America in leading dominant shares of the HGH market due to the latest technological developments. Increasing incidences of genetic disorders are ascribed to bolster the growth of this market. Also, the growing number of healthcare centers, even in rural areas, is increasing the market's demand to an extent. Increasing occurrences of genetic disorders and a rise in healthcare expenses are fueling the market growth. China is leading the market demand with technological advancements and increased disposable income. Japan is expected to have rapid growth in the human growth hormone market. Growing research and development activities with an increase in huge investments from the government are propelling the market growth.
The European HGH Market will grow at the highest CAGR in foreseen years, increasing support from public and private organizations. The increasing prevalence of the treatment of short stature is escalating the European regional market. The market in this region is driven by factors like private and public sectors showcasing their support in bringing awareness among humans. In addition, growing hormone deficiency disorders, increasing government expenses, and the growing significance of growth hormones for treating patients with Idiopathic Short Stature are propelling the market's demand. Germany is predicted to lead the market, followed by the UK.
The human growth hormone market in Latin America is expected to grow steadily. This is because the top companies' key players aim to increase their ability to produce to escalate the supply chain amid the rural areas, augmenting the market demand.
The Middle East and Africa HGH market anticipate having a prominent growth rate in the coming years. According to the Annals of Saudi Medicine's survey in 2015, the regular rate is registered as 0.2 per 10000 children in Saudi Arabia. In Kuwait, the growth hormone deficiency rate accounts for 38%, whereas the idiopathic short stature and Turner syndrome account for 20% and 12%.
Companies that are playing a dominating role in the global human growth hormone market profiled in the report are Pfizer Inc., Novo Nordisk A/S, Anhui Anke Biotechnology Co. Ltd., Eli Lilly, and Company, GeneScience Pharmaceuticals Co. Ltd., Genetech Inc., Novartis AG, Biopartners GmbH, Zhongshan Hygene Biopharm Co. Ltd., Merck KGaA, Ipsen S.A. and Lifetech Labs.
By Application
By Distribution Channel
By Region
Frequently Asked Questions
The global human growth hormone market was worth USD 4598 million in 2022 and is expected to be USD 4942 million in 2023.
Pfizer Inc., Eli Lilly and Company, Novartis AG, Merck & Co. Inc., and F. Hoffmann-La Roche Ltd. are some of the leading companies in the human growth hormone market.
The growth of the human growth hormone market is being driven by the increasing prevalence of growth hormone deficiency and other medical conditions that can be treated with HGH therapy. Additionally, advancements in technology and growing awareness about the benefits of HGH therapy are also contributing to market growth.
One of the biggest challenges facing the human growth hormone market is the high cost of HGH therapy, which can make it inaccessible to many patients. Additionally, there are concerns about the potential side effects of HGH therapy, including the risk of cancer.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region